Advertisement

< Back to Article

Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge

Fig 1

Efficacy of single-dose and prime-boost vaccination.

(A,B) Single-dose vaccination. IFNAR-/- mice (n = 9 for Ad-N; n = 6 for Ad-wt) were vaccinated with recombinant adenoviruses (1.25×107 ifu) 28 days prior to lethal CCHFV infection (1000 LD50). The animals were monitored for weight as a group (A) and disease progression/survival (B) over 30 days. (C,D) Prime-boost vaccination. IFNAR-/- mice (n = 9 for Ad-N; n = 3 for Ad-wt) were vaccinated with recombinant adenoviruses 56 (1.25×107 IFU; intramuscular) and 28 (108 IFU; intranasal) days prior to lethal CCHFV infection (1000 LD50). The animals were monitored for weight (C) and disease progression/survival (D) over 30 days. Data is reported as the means. *** p<0.001, ****p<0.0001.

Fig 1

doi: https://doi.org/10.1371/journal.pntd.0006628.g001